Westfield Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Westfield Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.7M	Buy	+314,914	New	+$27.5M	0.1%	199

Other funds holding DNTH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Westfield Capital Management's DNTH Position: Q2 2026 in Review

Westfield Capital Management opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 314,914 shares worth $30.7M. The stake represents 0.1% of the portfolio and ranks #199 among its holdings.

125 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Westfield Capital Management held 314,914 shares of Dianthus Therapeutics worth $30.7M as of Q2 2026.
Dianthus Therapeutics was a new Westfield Capital Management position in Q2 2026.
Dianthus Therapeutics made up 0.1% of Westfield Capital Management's portfolio in Q2 2026, its #199 holding.
125 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Westfield Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.